查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1771503

全球多發性硬化症治療藥物市場：市場規模、佔有率和趨勢分析（按藥物類別、給藥途徑、分銷管道和地區）、按細分市場預測（2025-2030 年）

Multiple Sclerosis Therapeutic Market Size, Share & Trends Analysis Report By Drug Class (Immunosuppressants, Immunostimulants), By Route Of Administration (Oral, Injectable), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

多發性硬化症藥物市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球多發性硬化症藥物市場規模預計到2030年將達到386.2億美元，2025年至2030年的複合年成長率為5.93%。

新興市場巨大的未滿足臨床需求是多發性硬化症藥物市場最具影響力的促進因素之一。全球許多組織積極參與傳播進行性多發性硬化症及其相關疾病的認知。其中，值得關注的例子包括美國多發性硬化症協會 (NMSS)、加拿大多發性硬化症國際聯合會、歐洲多發性硬化症平台 (EMSP) 和多發性硬化症協會 (MSC)。

預計報銷計畫也將增加多發性硬化症藥物的用量。例如，2014年6月，加拿大百健艾迪公司宣布，其多發性硬化症治療藥物TECFIDERA現已在英國哥倫比亞省透過BC省藥物補貼計畫（BC PharmaCare）獲得報銷。

預計劑量最小、成本低廉的新型治療方法的推出將進一步推動市場成長 - 例如，賽諾菲的 Lemtrada 每年只需服用三到五次，而 Copaxone 則需要每天服用。

多發性硬化症藥物市場：概述

  • 根據藥物類別，免疫抑制劑將在 2024 年佔據市場主導地位，收入為 60.50%。強大的藥物管道和未來六年內預期的商業化是預計推動市場成長的一些因素。
  • 根據給藥途徑，口服製劑在預測期內預計將以最快的複合年成長率成長。
  • 2024年，注射劑市場佔有最大佔有率，為52.50%。
  • 到 2024 年，北美將佔據全球市場的主導地位，佔有 38.28% 的佔有率。多發性硬化症盛行率的上升、新藥的推出以及美國Tysabri和 Overgeo 等藥品價格高昂是推動其主導的一些因素。

目錄

第1章 分析方法與範圍

第2章執行摘要

3. 多發性硬化症藥物市場：促進因素、趨勢與範圍

  • 市場概況/相關展望
  • 市場規模和成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 多發性硬化症藥物市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL分析

第4章 多發性硬化症藥物市場：按藥物類別的估計和趨勢分析

  • 細分儀表板
  • 多發性硬化症藥物市場：以藥物類別進行趨勢分析（2024 年和 2030 年）
  • 免疫抑制劑
  • 免疫促效劑

第5章 多發性硬化症藥物市場：依給藥途徑的估計與趨勢分析

  • 細分儀表板
  • 多發性硬化症藥物市場：按給藥途徑分類的趨勢分析（2024 年和 2030 年）
  • 口服
  • 注射
  • 其他

第6章 多發性硬化症藥物市場：按分銷管道進行的估計和趨勢分析

  • 細分儀表板
  • 多發性硬化症藥物市場：按分銷管道分類的趨勢分析（2024 年和 2030 年）
  • 醫院藥房
  • 零售藥局
  • 電子商務

第7章多發性硬化症藥物市場：按地區估計和趨勢分析

  • 多發性硬化症藥物市場佔有率（2024 年及 2030 年）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司分類
  • 公司熱圖分析
  • 公司簡介
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Biogen
    • Bayer AG
    • Sanofi
    • F. Hoffman-La Roche Ltd
    • Johnson &Johnson Services, Inc.
    • Merck &Co., Inc.
    • Takeda Pharmaceuticals Company Limited.
    • Horizon Therapeutics plc
Product Code: 978-1-68038-833-6

Multiple Sclerosis Therapeutic Market Growth & Trends:

The global multiple sclerosis therapeutic market size is estimated to reach USD 38.62 billion by 2030, registering a CAGR of 5.93% from 2025 to 2030, according to a new report by Grand View Research, Inc. The presence of high unmet clinical needs in developing regions is one of the highest impact rendering drivers of the multiple sclerosis therapeutics market. Many organizations over the globe are actively involved in spreading awareness among people regarding progressive multiple sclerosis and the symptoms associated with it. Some notable examples include the National Multiple Sclerosis Society (NMSS) in the U.S., Multiple Sclerosis International Federation in Canada, European Multiple Sclerosis Platform (EMSP), and the Multiple Sclerosis Society (MSC).

Reimbursement programs are also anticipated to enhance the penetration of multiple sclerosis drugs. For instance, In June 2014, Biogen Idec Canada, announced that its TECFIDERA drug for the treatment of MS is available for reimbursement in British Colombia through B.C PharmaCare.

The introduction of novel therapeutics with minimal dosage requirement and cost-effectiveness is further expected to favor market growth. For, instance Lemtrada by Sanofi needs to be administered 3-5 times per year as compared to Copaxone, which requires daily administration.

Multiple Sclerosis Therapeutic Market Report Highlights:

  • Based on drug class, the immunosuppressant segment dominated the market with the largest revenue share of 60.50% in 2024. The presence of a strong drug pipeline and its expected commercialization in the coming six years are some factors expected to drive market growth.
  • Based on route of administration, the oral segment is expected to grow at the fastest CAGR rate over the forecast period, propelled by increasing patient preference for convenient, home-based treatment options.
  • In 2024, the injectable market held the largest share of 52.50% in 2024, owing to high prescription rates & price.
  • North America dominated the global market with a share of 38.28% in 2024. The increasing prevalence of multiple sclerosis, the introduction of new drugs, and high prices of drugs, such as Tysabri and Aubagio in the U.S., are some factors responsible for its dominance.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Multiple Sclerosis Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Multiple Sclerosis Therapeutic Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape
    • 3.4.3. Pipeline Analysis, By Phase

Chapter 4. Multiple Sclerosis Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Multiple Sclerosis Therapeutic Market: Drug Class Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Immunosuppressants
    • 4.3.1. Immunosuppressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Immunostimulants
    • 4.4.1. Immunostimulants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Multiple Sclerosis Therapeutics Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Multiple Sclerosis Therapeutic Market: Route of Administration Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Oral
    • 5.3.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Injectable
    • 5.4.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Multiple Sclerosis Therapeutics Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Multiple Sclerosis Therapeutic Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. E-Commerce
    • 6.5.1. E-Commerce Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Multiple Sclerosis Therapeutic Market: Regional Estimates & Trend Analysis

  • 7.1. Multiple Sclerosis Therapeutic Market Share, By Region, 2024 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Teva Pharmaceutical Industries Ltd.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Pfizer Inc.
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Biogen
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Bayer AG
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Sanofi
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. F. Hoffman-La Roche Ltd
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Johnson & Johnson Services, Inc.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Merck & Co., Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Takeda Pharmaceuticals Company Limited.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Horizon Therapeutics plc
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 4 Global Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 5 Global Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 6 North America Multiple Sclerosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 7 North America Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 8 North America Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 9 North America Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 U.S Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 11 U.S Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 12 U.S Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 Canada Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 14 Canada Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 15 Canada Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Mexico Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 17 Mexico Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 18 Mexico Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Europe Multiple Sclerosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 20 Europe Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 21 Europe Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 22 Europe Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 UK Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 24 UK Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 25 UK Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 Germany Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 27 Germany Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million))
  • Table 28 Germany Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 France Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 30 France Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 31 France Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Italy Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 33 Italy Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 34 Italy Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 Spain Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 36 Spain Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 37 Spain Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Denmark Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 39 Denmark Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 40 Denmark Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Sweden Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 42 Sweden Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 43 Sweden Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Norway Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 45 Norway Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 46 Norway Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Multiple Sclerosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 Japan Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 52 Japan Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 53 Japan Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 China Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 55 China Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 56 China Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 India Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 58 India Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 59 India Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 South Korea Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 61 South Korea Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 62 South Korea Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 Australia Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 64 Australia Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 65 Australia Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 Thailand Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 67 Thailand Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 68 Thailand Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 69 Latin America Multiple Sclerosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 70 Latin America Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 71 Latin America Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 72 Latin America Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 Brazil Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 74 Brazil Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 75 Brazil Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 Argentina Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 77 Argentina Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 78 Argentina Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Multiple Sclerosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 83 South Africa Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 84 South Africa Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 85 South Africa Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 UAE Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 87 UAE Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 88 UAE Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 91 Kuwait Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Multiple Sclerosis Therapeutics Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 Penetration & Growth Prospect Mapping
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Multiple Sclerosis Therapeutics market: Drug Class outlook and key takeaways
  • Fig. 15 Multiple Sclerosis Therapeutics market: Drug Class movement analysis & market share 2024 & 2030
  • Fig. 16 Immunosuppressants market, 2018 - 2030 (USD Million)
  • Fig. 17 Immunostimulants market, 2018 - 2030 (USD Million)
  • Fig. 18 Multiple Sclerosis Therapeutics market: Route of Administration outlook and key takeaways
  • Fig. 19 Multiple Sclerosis Therapeutics market: Route of Administration movement analysis & market share 2024 & 2030
  • Fig. 20 Oral Multiple Sclerosis Therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 21 Injectable Multiple Sclerosis Therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 22 Others Multiple Sclerosis Therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 23 Multiple Sclerosis Therapeutics market: Distribution Channel outlook and key takeaways
  • Fig. 24 Multiple Sclerosis Therapeutics market: Distribution Channel movement analysis & market share 2024 & 2030
  • Fig. 25 Hospital Pharmacies, 2018 - 2030 (USD Million)
  • Fig. 26 Retail Pharmacies, 2018 - 2030 (USD Million)
  • Fig. 27 E-Commerce, 2018 - 2030 (USD Million)
  • Fig. 28 Regional Marketplace: Key Takeaways
  • Fig. 29 Regional Outlook, 2024 & 2030
  • Fig. 30 Regional Market Dashboard
  • Fig. 31 Regional Market Place: Key Takeaways
  • Fig. 32 North America
  • Fig. 33 North America Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. Key Country Dynamics
  • Fig. 35 U.S. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Canada Key Country Dynamics
  • Fig. 37 Canada Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Mexico Key Country Dynamics
  • Fig. 39 Mexico Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Europe
  • Fig. 41 Europe Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 42 UK Key Country Dynamics
  • Fig. 43 UK Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Germany Key Country Dynamics
  • Fig. 45 Germany Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 46 France Key Country Dynamics
  • Fig. 47 France Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Italy Key Country Dynamics
  • Fig. 49 Italy Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Spain Key Country Dynamics
  • Fig. 51 Spain Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Denmark Key Country Dynamics
  • Fig. 53 Denmark Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Sweden Key Country Dynamics
  • Fig. 55 Sweden Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 56 Norway Key Country Dynamics
  • Fig. 57 Norway Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 58 Asia Pacific
  • Fig. 59 Asia-Pacific Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 60 Japan Key Country Dynamics
  • Fig. 61 Japan Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 62 China Key Country Dynamics
  • Fig. 63 China Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 64 India Key Country Dynamics
  • Fig. 65 India Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 66 Australia Key Country Dynamics
  • Fig. 67 Australia Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 68 Thailand Key Country Dynamics
  • Fig. 69 Thailand Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 70 South Korea Key Country Dynamics
  • Fig. 71 South Korea Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Latin America
  • Fig. 73 Latin America Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Brazil Key Country Dynamics
  • Fig. 75 Brazil Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 76 Argentina Key Country Dynamics
  • Fig. 77 Argentina Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 78 MEA
  • Fig. 79 MEA Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 80 South Africa Key Country Dynamics
  • Fig. 81 South Africa Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 82 Saudi Arabia Key Country Dynamics
  • Fig. 83 Saudi Arabia Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 84 UAE Key Country Dynamics
  • Fig. 85 UAE Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 86 Kuwait Key Country Dynamics
  • Fig. 87 Kuwait Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 88 Strategy Mapping